A BRAFV600E mutation specific antibody is available (169) and a recent small study suggested that vemurafenib (a BRAF inhibitor with significant activity against BRAF mutated metastatic melanoma) may improve outcomes in adults with recurrent BRAFV600E mutated PXA (170). Here, BRAF is linked to metastatic melanoma.